登入
選單
返回
Google圖書搜尋
S100A9-imaging Enables Estimation of Early Therapy-mediated Changes in the Inflammatory Tumor Microenvironment
Anne Helfen
Annika Schnepel
Jan Rieß
Miriam Stölting
Mirjam Gerwing
Max Masthoff
Thomas J. Vogl
Johannes Roth
Carsten Höltke
Moritz Wildgruber
Michel Eisenblätter
出版
Universität
, 2021
URL
http://books.google.com.hk/books?id=L4ZszgEACAAJ&hl=&source=gbs_api
註釋
Abstract: (1) Background: The prognosis of cancer is dependent on immune cells in the tumor microenvironment (TME). The protein S100A9 is an essential regulator of the TME, associated with poor prognosis. In this study, we evaluated early therapy effects on the TME in syngeneic murine breast cancer via S100A9-specific in vivo imaging. (2) Methods: Murine 4T1 cells were implanted orthotopically in female BALB/c mice (n = 59). Tumor size-adapted fluorescence imaging was performed before and 5 days after chemo- (Doxorubicin, n = 20), anti-angiogenic therapy (Bevacizumab, n = 20), or placebo (NaCl, n = 19). Imaging results were validated ex vivo (immunohistochemistry, flow cytometry). (3) Results: While tumor growth revealed no differences (p = 0.48), fluorescence intensities (FI) for S100A9 in Bevacizumab-treated tumors were significantly lower as compared to Doxorubicin (2.60 vs. 15.65 AU, p
